Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Dry eye syndrome is a chronic and typically progressive condition. Depending on its cause and severity, it may not be completely curable. But in most cases, dry eyes can be managed successfully, usually resulting in noticeably greater eye comfort, fewer dry eye symptoms, and sometimes sharper vision as well. Because dry eye disease can have a number of causes, a variety of treatment approaches are used. Furthermore, in China, standard eye product care is growing steadily and dry eye products are accounted for highest value, owing to high growing demand from the working-age population disease and school/university students. Meanwhile, manufacturer’s continuous efforts to educate consumers increased awareness of eye care products amongst Chinese consumers. Likewise, the prevalence of dry eye syndrome is increasing in Japan. Dry eye syndrome is common disorder of eye affecting a significant percentage of population. Especially, those older than 50 years of age, middle aged and older adults are commonly affected group.
Increasing healthcare expenditure & patient awareness, technological advancements in Asia Pacific dry eye syndrome therapeutics, high prevalence and rise in incidence rates of dry eye disease are some the major factors driving the growth of the Asia Pacific dry eye syndrome therapeutics market. On the other hand, factors such as alternative therapies and high cost of specialty dry eye products are hampering the growth of the market.
The Asia Pacific dry eye syndrome therapeutics market is classified into product type, disease type and country.
The products discussed in this report are cyclosporine, oral corticosteroid, artificial tears, omega supplements, punctal plugs and others. Furthermore, punctual plugs segment is classified into removable and dissolvable. Likewise, others segment include lid wipes, eye mask and specialized eye wares. Among various product types, the cyclosporine segment accounted for the largest market share in the Asia Pacific dry eye syndrome therapeutics market in 2018. There are few alternatives which are as effective as cyclosporine which is helping the drug to hold strong dominance in the market.
Various disease types of Asia Pacific dry eye syndrome therapeutics market are covered in the report such as evaporative dry eye syndrome and aqueous dry eye syndrome. The aqueous dry eye syndrome segment dominated the market in 2018. This syndrome is caused by the tear gland damage, increase in the age and when the lacrimal gland fails to produce enough tears to coat the surface of the eye. Whereas, the market for evaporative dry eye syndrome is also projected to increase rapidly.
The Asia Pacific dry eye syndrome therapeutics market report is studied across the key countries India, China, Japan and Rest of the Asia Pacific. The Asia-Pacific region is projected to grow at a fastest CAGR during the forecast period. Growing incidence of dry eye disease is seen to give strong momentum for the growth in this region. Increasing healthcare expenditure & patient awareness and presence of key players within the region are the promising factors for growth of the market in the country.
The key players profiled in the global Asia Pacific dry eye syndrome therapeutics market are Allergan Plc, AFT pharmaceuticals, Akorn, Inc, Bausch Health Companies Inc, Rohto Pharmaceutical Co., Ltd., I-Med Pharma Inc, Johnson and Johnson Vision care, Inc. (Johnson & Johnson), Medicom Healthcare, Alcon Laboratories, Inc. (Novartis AG), OASIS Medical, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings), Reckitt Benckiser Group PLC, Santen Pharmaceutical Co Ltd, Sentiss Pharma Private limited, Shire Plc, Bayer AG, Sun Pharmaceutical Industries Limited, among others. Leading companies have invested massive capital in research & development and mergers & acquisitions activities to develop innovative products in the market.
The Asia Pacific dry eye syndrome therapeutics market is classified into product type, disease type and geography. The products discussed in this report are cyclosporine, oral corticosteroid, artificial tears, omega supplements, punctal plugs and others. Furthermore, punctual plugs segment is classified into removable and dissolvable. Likewise, others segment include lid wipes, eye mask and specialized eye wares. Among various product types, the cyclosporine segment accounted for the largest market share in the Asia Pacific dry eye syndrome therapeutics market in 2018. There are few alternatives which are as effective as cyclosporine which is helping the drug to hold strong dominance in the market.
Various disease types of Asia Pacific dry eye syndrome therapeutics market are covered in the report such as evaporative dry eye syndrome and aqueous dry eye syndrome. The aqueous dry eye syndrome segment dominated the market in 2018. This syndrome is caused by the tear gland damage, increase in the age and when the lacrimal gland fails to produce enough tears to coat the surface of the eye. Whereas, the market for evaporative dry eye syndrome is also projected to increase rapidly.
The Asia Pacific dry eye syndrome therapeutics market report is studied across the key countries India, China, Japan and Rest of the Asia Pacific. The Asia-Pacific region is projected to grow at a fastest CAGR during the forecast period. Growing incidence of dry eye disease is seen to give strong momentum for the growth in this region. Increasing healthcare expenditure & patient awareness and presence of key players within the region are the promising factors for growth of the market in the country.
Why to buy this report:
